Is Cogent Biosciences Stock a Good Investment?
Cogent Biosciences Investment Advice | COGT |
- Examine Cogent Biosciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Cogent Biosciences' leadership team and their track record. Good management can help Cogent Biosciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Cogent Biosciences' business and its evolving consumer preferences.
- Compare Cogent Biosciences' performance and market position to its competitors. Analyze how Cogent Biosciences is positioned in terms of product offerings, innovation, and market share.
- Check if Cogent Biosciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Cogent Biosciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Cogent Biosciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Cogent Biosciences is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Cogent Biosciences Stock
Researching Cogent Biosciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 100.0% of the company shares are held by institutions such as insurance companies. The book value of Cogent Biosciences was currently reported as 1.85. The company recorded a loss per share of 2.48. Cogent Biosciences last dividend was issued on the 9th of November 2020. The entity had 1:4 split on the 9th of November 2020.
To determine if Cogent Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cogent Biosciences' research are outlined below:
| Cogent Biosciences generated a negative expected return over the last 90 days | |
| Cogent Biosciences has high historical volatility and very poor performance | |
| Net Loss for the year was (192.41 M) with loss before overhead, payroll, taxes, and interest of (121.63 M). | |
| Cogent Biosciences currently holds about 325.56 M in cash with (153.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95. | |
| Cogent Biosciences has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies |
Cogent Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cogent Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cogent Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Cogent Biosciences' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 887.01 M.Basic technical analysis of Cogent Stock
As of the 17th of February 2025, Cogent Biosciences shows the Mean Deviation of 2.5, risk adjusted performance of (0.02), and Standard Deviation of 3.52. Cogent Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Cogent Biosciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cogent Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cogent Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cogent Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cogent Biosciences' Outstanding Corporate Bonds
Cogent Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cogent Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cogent bonds can be classified according to their maturity, which is the date when Cogent Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| CCOI 7 15 JUN 27 Corp BondUS19240CAE30 | View | |
| US19240CAC73 Corp BondUS19240CAC73 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Cogent Biosciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Cogent Biosciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.15) | |||
| Mean Deviation | 2.5 | |||
| Coefficient Of Variation | (2,571) | |||
| Standard Deviation | 3.52 | |||
| Variance | 12.4 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.15) | |||
| Total Risk Alpha | (0.15) | |||
| Treynor Ratio | (0.16) | |||
| Maximum Drawdown | 18.81 | |||
| Value At Risk | (5.07) | |||
| Potential Upside | 5.43 | |||
| Skewness | 0.4158 | |||
| Kurtosis | 1.68 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.15) | |||
| Mean Deviation | 2.5 | |||
| Coefficient Of Variation | (2,571) | |||
| Standard Deviation | 3.52 | |||
| Variance | 12.4 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.15) | |||
| Total Risk Alpha | (0.15) | |||
| Treynor Ratio | (0.16) | |||
| Maximum Drawdown | 18.81 | |||
| Value At Risk | (5.07) | |||
| Potential Upside | 5.43 | |||
| Skewness | 0.4158 | |||
| Kurtosis | 1.68 |
Consider Cogent Biosciences' intraday indicators
Cogent Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cogent Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Cogent Biosciences time-series forecasting models is one of many Cogent Biosciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cogent Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Cogent Stock media impact
Far too much social signal, news, headlines, and media speculation about Cogent Biosciences that are available to investors today. That information is available publicly through Cogent media outlets and privately through word of mouth or via Cogent internal channels. However, regardless of the origin, that massive amount of Cogent data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cogent Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cogent Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cogent Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cogent Biosciences alpha.
Cogent Biosciences Corporate Management
| Rachael MD | VP Development | Profile | |
| Sara Saltzman | VP Affairs | Profile | |
| Jessica MD | Chief Officer | Profile | |
| Brad Fell | Senior Chemistry | Profile | |
| Christi Waarich | Senior Relations | Profile | |
| Brad Barnett | Chief Officer | Profile |
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.